Cosmax, Inc.

KOSE:A192820 Stock Report

Market Cap: ₩1.5t

Cosmax Valuation

Is A192820 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A192820 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A192820 (₩129300) is trading below our estimate of fair value (₩296691.56)

Significantly Below Fair Value: A192820 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A192820?

Key metric: As A192820 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A192820. This is calculated by dividing A192820's market cap by their current earnings.
What is A192820's PE Ratio?
PE Ratio20.1x
Earnings₩72.86b
Market Cap₩1.49t

Price to Earnings Ratio vs Peers

How does A192820's PE Ratio compare to its peers?

The above table shows the PE ratio for A192820 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.6x
A002790 AMOREPACIFIC Group
7.8x2.8%₩1.8t
A278470 APR
21.5x25.7%₩1.9t
A018290 VT
20.2xn/a₩1.0t
A241710 Cosmecca Korea
16.7x22.4%₩600.2b
A192820 Cosmax
20.1x27.3%₩1.5t

Price-To-Earnings vs Peers: A192820 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the peer average (16.7x).

Price to Earnings Ratio vs Industry

How does A192820's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A900120 CXI Healthcare Technology Group
0.8xn/aUS$16.21m
No more companies available in this PE range
A192820 20.1xIndustry Avg. 17.3xNo. of Companies6PE0816243240+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A192820 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the KR Personal Products industry average (17.3x).

Price to Earnings Ratio vs Fair Ratio

What is A192820's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A192820 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.1x
Fair PE Ratio19.8x

Price-To-Earnings vs Fair Ratio: A192820 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A192820 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩129,400.00
₩190,857.14
+47.5%
10.9%₩239,000.00₩160,000.00n/a21
Nov ’25₩153,200.00
₩190,833.33
+24.6%
11.5%₩239,000.00₩160,000.00n/a18
Oct ’25₩146,000.00
₩191,000.00
+30.8%
11.7%₩239,000.00₩160,000.00n/a17
Sep ’25₩121,300.00
₩191,687.50
+58.0%
12.0%₩239,000.00₩160,000.00n/a16
Aug ’25₩154,000.00
₩217,062.50
+40.9%
10.3%₩250,000.00₩179,000.00n/a16
Jul ’25₩189,100.00
₩202,062.50
+6.9%
8.9%₩239,000.00₩170,000.00n/a16
Jun ’25₩170,000.00
₩198,875.00
+17.0%
8.3%₩230,000.00₩170,000.00n/a16
May ’25₩140,100.00
₩173,625.00
+23.9%
11.4%₩223,000.00₩124,000.00n/a16
Apr ’25₩130,000.00
₩164,937.50
+26.9%
9.1%₩180,000.00₩124,000.00n/a16
Mar ’25₩107,600.00
₩173,250.00
+61.0%
7.2%₩200,000.00₩145,000.00n/a16
Feb ’25₩113,700.00
₩173,250.00
+52.4%
7.2%₩200,000.00₩145,000.00n/a16
Jan ’25₩126,400.00
₩172,062.50
+36.1%
7.2%₩200,000.00₩145,000.00n/a16
Dec ’24₩112,100.00
₩164,058.82
+46.4%
15.1%₩200,000.00₩100,000.00n/a17
Nov ’24₩133,600.00
₩163,533.33
+22.4%
15.7%₩200,000.00₩100,000.00₩153,200.0015
Oct ’24₩128,700.00
₩158,928.57
+23.5%
16.7%₩192,000.00₩100,000.00₩146,000.0014
Sep ’24₩151,800.00
₩157,500.00
+3.8%
16.4%₩192,000.00₩100,000.00₩121,300.0014
Aug ’24₩101,900.00
₩118,714.29
+16.5%
10.7%₩141,000.00₩100,000.00₩154,000.0014
Jul ’24₩93,000.00
₩109,214.29
+17.4%
12.7%₩130,000.00₩70,000.00₩189,100.0014
Jun ’24₩81,100.00
₩108,142.86
+33.3%
12.1%₩130,000.00₩70,000.00₩170,000.0014
May ’24₩77,200.00
₩99,916.67
+29.4%
11.7%₩115,000.00₩70,000.00₩140,100.0012
Apr ’24₩81,000.00
₩99,500.00
+22.8%
11.8%₩115,000.00₩70,000.00₩130,000.0012
Mar ’24₩77,300.00
₩87,923.08
+13.7%
16.0%₩115,000.00₩65,000.00₩107,600.0013
Feb ’24₩78,400.00
₩88,428.57
+12.8%
14.9%₩107,000.00₩65,000.00₩113,700.0014
Jan ’24₩74,100.00
₩76,461.54
+3.2%
14.6%₩103,000.00₩65,000.00₩126,400.0013
Dec ’23₩63,300.00
₩77,428.57
+22.3%
16.9%₩103,000.00₩60,000.00₩112,100.0014
Nov ’23₩47,800.00
₩81,571.43
+70.7%
19.6%₩103,000.00₩60,000.00₩133,600.0014

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

NeoPharm

₩193.5b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,840.00

7D

-9.1%

1Y

3.0%

NOVAREXLtd

₩136.0b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,650.00

7D

-18.7%

1Y

-31.5%

Cosmecca Korea

₩600.2b

Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.

A241710

₩53,900.00

7D

-13.6%

1Y

44.3%